European Journal of Cancer
Volume 43, Issue 16 , Pages 2345-2350, November 2007

Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer☆☆☆

  • Wouter K. de Jong

      Affiliations

    • Department of Pulmonology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Harry J.M. Groen

      Affiliations

    • Department of Pulmonology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 (0)50 3616161; fax: +31 (0)50 3619320.
    • ,
  • Mia G.J. Koolen

      Affiliations

    • Department of Pulmonology, Academy Medical Center, Amsterdam, The Netherlands
    • ,
  • Bonne Biesma

      Affiliations

    • Department of Pulmonology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands
    • ,
  • Luuk N.A. Willems

      Affiliations

    • Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • Hian-Bie Kwa

      Affiliations

    • Department of Pulmonology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    • ,
  • Aart van Bochove

      Affiliations

    • Department of Medicine, Zaans Medisch Centrum, Zaandam, The Netherlands
    • ,
  • Harm van Tinteren

      Affiliations

    • Comprehensive Cancer Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • Egbert F. Smit

      Affiliations

    • Department of Pulmonology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

Received 26 May 2007; received in revised form 13 July 2007; accepted 31 July 2007. published online 10 September 2007.

Abstract 

The progression-free survival (PFS) of cyclophosphamide/doxorubicin/etoposide (CDE) and carboplatin/paclitaxel (CP) was compared in chemonaive patients with extensive disease small-cell lung cancer (ED-SCLC). A total of 203 patients were randomised to three-weekly CDE (n=102) or CP (n=101) for five cycles. Tumour response rates in CDE and CP were 60% and 61%. PFS of CP was 5.2 months, PFS of CDE 4.9 months (p=0.60). The major difference in toxicity between CDE and CP was grade 4 leukocytopaenia in 64% and 9% of the patients (p<0.0001), leading to febrile neutropaenia in 30% and 4% of the patients (p<0.0001), respectively. This was the reason for differences in the total number of hospital admissions (63 for CDE and 40 for CP, p=0.0025).

This study failed to demonstrate any benefit in PFS with CP compared with CDE. CP was associated with significantly less haematological toxicity, leading to 37% less hospital admissions for febrile neutropaenia.

Keywords: Small-cell lung cancer, Chemotherapy, Extensive disease, Phase III study

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This study was presented in part at the 41st Annual meeting of the American Society of Clinical Oncology, Orlando, FL, May 13–17, 2005, and at the 11th World Conference on Lung Cancer, Barcelona, Spain, July 3–6, 2005.

☆☆ Registered at www.clinicaltrials.gov, NCT00003696.

PII: S0959-8049(07)00587-4

doi:10.1016/j.ejca.2007.07.029

European Journal of Cancer
Volume 43, Issue 16 , Pages 2345-2350, November 2007

Article Tools

* Image Usage & Resolution